Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

75 Views

Physician

Resident

NewPractitioner

Session: GU: Organ Preservation and Personalization: Advancing Paradigms for Prostate, Bladder, and Kidney Cancer

2 - Stereotactic Ablative Radiotherapy for Primary and Metastatic Renal Cell Carcinoma

Friday, March 15, 2024

2:45 PM - 4:15 PM ET

Location: Grand Ballroom VI-VIII

Speaker(s)

Anand Swaminath, MD

Radiation Oncologist
McMaster University/ Juravinski Cancer Centre

Disclosure(s): AstraZeneca: Consultant/Advisory Board (Ongoing), Honoraria (Ongoing); Bristol-Myers Squibb: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated)

PDF Slides

Disclosure(s):

Anand Swaminath, MD: AstraZeneca: Consultant/Advisory Board (Ongoing), Honoraria (Ongoing); Bristol-Myers Squibb: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated)

Learning Objectives:

Understand the rationale, scope, and current landscape of SABR for primary renal cell carcinoma (RCC)
Identify the challenges currently facing radiation oncologists when managing patients with SABR for RCC (indications, dose/fractionation issues, impact on renal function, response assessment post therapy, and comparison with other local modalities)
Discuss the role SABR plays in the metastatic RCC setting, in combination with immunotherapy, as well as for cytoreductive SABR for de novo metastatic disease